The full peptide antagonist of the pancreatic cholecystokinin (CCK) receptor, JMV 179, [BocTyr(S0,H)-Ahx-Gly-dTrp-Ahx-Asp phenylethyl ester, where Tyr(S0,H) = sulfated tyrosine, Ahx = 6-aminohexanoic acid] was modified at its N-terminus by incorporation of p-hydroxyphenyl propionate (Bolton-Hunter reagent, BH) and was subsequently radioiodinated. After HPLC purification, lZ51-BH-JMV-179, a CCK antagonist radioligand of high specific activity (2000 CUmmol) was obtained. '251-BH-JMV-179 bound to a single population of sites on rat pancreatic plasma membranes, (K, = 3.9 nM, B,,, = 40 pmoVmg protein). Binding was dependent on time, temperature, and protein concentration, and was fully reversible. JMV 179 radioligand detected four times as many sites This study, with the first CCK peptide antagonist radioligand, demonstrates that CCK receptors exist in two interconvertible affhity states regulated by guanine-nucleotide-binding regulatory protein(s) in rat pancreatic plasma membranes. JMV 179 radioligand does not induce receptor coupling but distinguishes the two affinity states of the CCK receptors. JMV 179 reveals the existence of populations of high-affinity and low-affinity sites for CCK which had not previously been detected by agonist radioligand binding, thus suggesting heterogeneity of CCK receptor sites in membranes.Studies during the last decade have abundantly documented the wide distribution of cholecystokinin (CCK) peptides within the gastrointestinal tract as well as the nervous system [l]. Pancreatic acinar cells from rat possess only Asubtype CCK receptors [2-41, the occupation of which by CCK agonists stimulates enzyme exocytosis [ 5 ] . The recent cloning and sequencing of the CCK receptor cDNA has provided important information [6]. However, many questions